Skip to main content
. Author manuscript; available in PMC: 2010 Oct 7.
Published in final edited form as: Alcohol Clin Exp Res. 2008 Jul;32(7):1159–1166. doi: 10.1111/j.1530-0277.2008.00735.x

Table 1.

Demographic and clinical characteristics by treatment condition.1

Nalmefene
(n=166)
Placebo
(n=106)
Statistic P-value
Age [mean yr (SD)] 49.8 (9.1) 49.3 (8.8) F(1,270)=.22 P=.64
Women (%) 32 (19.3%) 20 (18.9%) χ2 =.01, df=1 P=.93
Family history of alcoholism
(%)
92 (55.4%) 63 (59.4%) χ2 =.43, df=1 P=.52
Previous alcohol treatments (#) 1.3 (2.9) 1.5 (3.7) F(1,270)=.28 P=.60
Number of DSM-IV alcohol
dependence symptoms)
6.6 (1.6) 6.8 (1.4) F(1,270)=.53 P=.47
Alcohol Dependence Scale
score
17.5 (6.9) 18.3 (7.2) F(1,270)=.83 P=.36
Heavy drinking days1per week 3.8 (1.7) 4.2 (1.7) F(1,270)=3.81 P=.052
Very heavy drinking days2per
week
2.0 (1.8) 2.1 (1.7) F(1,270)=.08 P=.77
Abstinent days per week 2.5 (1.7) 2.1 (1.7) F(1,270)=3.94 P=.048
Beck Depression Inventory
score
13.8 (7.5) 14.2 (8.6) F(1,270)=.14 P=.71
Beck Anxiety Inventory score 9.2 (7.5) 11.0 (10.0) F(1,270)=2.78 P=.097
*

Values are mean (SD) or number (%)

1

Days on which men consumed ≥5 and women consumed ≥4 standard drinks

2

Days on which men consumed ≥10 and women consumed ≥8 standard drinks